According to the health ministry, Japan's number of dementia patients who are 65 years of age or older will rise to 7 million in 2025, from the current 6 million.
The drug, however, does not work for everyone and — as with other Alzheimer's drugs that target plaques in the brain — can cause dangerous side effects such as brain swelling and bleeding in rare cases. Eisai said it will conduct a post-marketing special use survey in all patients administered the drug until enough data is collected from unspecified number of patients under Japanese health ministry procedures.
The drug will be partially covered by health insurance and is expected to be ready for clinical use by the end of the year. The price is yet to be decided but is expected to be expensive, Kyodo News agency reported. Eisai is committed to delivering Leqembi to people who need it and their families “as a new treatment,” said Haruo Naito, the company’s CEO.The Alzheimer's Association created a list of early signs of the disease or other types of dementia. In the United States, the disease disproportionately affects Hispanic patients.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: AP - 🏆 728. / 51 Read more »
Source: ScienceAlert - 🏆 63. / 68 Read more »
Source: ScienceDaily - 🏆 452. / 53 Read more »
Source: PennLive - 🏆 463. / 53 Read more »